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ABSTRACT 
Objective: To determine frequency and types of infections devel- 
oped by renal allograft recipients following transplantation and 
to relate these to their immunosuppressive therapy. 
Design: Descriptive, prospective study. 
Methods: At the National Kidney Institute (NKI), 513 kidney 
graft recipients were followed for 1 year for hospital admis- 
sions due to infectious disease. All patients were free of active 
infection before transplantation. Criteria for the diagnosis of 
infection after transplantation, including fever work-up, were 
provided in transplant protocols. Patients were given double or 
triple immunosuppressive regimens. 
Results: Infection was highest during the first 3 months fol- 
lowing transplantation. Bacterial and viral infections were noted 
early, whereas fungal infections and tuberculosis occurred later 
in the first year following transplantation. Pneumonia and uri- 
nary tract infections were the most common bacterial infec- 
tions observed. Amoebiasis and malaria were observed more 
in patients on cyclosporine and triple regimens. Nocardiosis 
occurred more frequently among patients on azathioprine. 
Conclusion: More tropical infectious diseases were observed. 
Early reduction of prednisone in the triple regimen resulted in 
more rejection episodes but less infection episodes. Rejection 
therapy influenced the outcome of post-transplant infections. 
Key Words: Philippines, transplant infections 
Int J Infect Dis 1997: 1:222-225. 
Following an organ transplant, immunosuppressive ther- 
apy designed to prevent the rejection of the graft, may 
also prevent the normal immune response to infection. 
Reports on the frequency and pattern of infections after 
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an organ transplant have primarily originated from devel- 
oped countries.1-3 There are a few reports from devel- 
oping countries, especially from the tropics, on infectious 
complications of transplantation.4-7 
Although the first kidney transplant in the Philip- 
pines was performed more than 20 years ago, full support 
and implementation of the transplantation program 
started only in 1983. At the National Kidney Institute 
(NKI), the primary transplant center in the country, 1019 
kidney transplants have been performed in 1008 recipi- 
ents, as of December 1994. Five hundred thirteen of these 
recipients were prospectively followed for at least 1 year 
following transplantation for hospital admission due to 
infectious disease, to determine frequency and types of 
infections they developed and to relate these to their 
immunosuppressive therapy. 
MATERIAL AND METHODS 
Pretransplant Protocol 
At the start of the transplant program, algorithms and 
protocols were provided to house staff physicians for 
work-up of common infectious disease problems before 
and after transplant and for adjustment of immunosup- 
pressive regimens. 
The transplant protocol at the NKI required that both 
donor and recipient be free of infection at the time of 
transplant. Donors positive for hepatitis B surface anti- 
gen (HBsAg) and with abnormal liver function tests were 
disqualified. Recipients who were hepatitis B virus (HBV) 
carriers were not disqualified. Anti-hepatitis C virus (anti- 
HCV) tests were not done because the test became avail- 
able in the country only in 1994. Recipients excluded 
from the transplant program were those over 60 years of 
age and those with chronic active hepatitis. Pretransplant 
serologies were also done for cytomegalovirus (CMV) 
and Epstein-Barr virus (EBV). Transplant surgery was 
deferred for recipients with active pulmonary tubercu- 
losis (TB) until after 2 months of intensive therapy and 
sputum conversion; maintenance therapy was continued 
after transplant. 
Patients with a history of adequate anti-H3 treatment, 
positive PPD, and with scarring or calcified infiltrates 
shown on chest x-ray were given isoniazid prophylaxis 
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following transplantation. Prophylactic antibiotics were 
given during transplant surgery only. Cotrimoxazole pro- 
phylaxis was given for 1 month after transplant when 
cyclosporine dose was reduced to 4 mg/kg per day. 
Immunosuppressive Protocol 
A total of 513 patients were included in the study. Sev- 
enteen percent of those on double therapy, 22% on triple 
therapy, and 20% on triple low-dose prednisone received 
cadaver kidneys.These patients were divided into three 
immunosuppressive protocols. The first group received 
the double therapy of either azathioprine (AZA) or 
cyclosporine (CYA) plus prednisone (Pred), and the sec- 
ond group received triple therapy of AZA, CYA, and Pred 
during the first 3 months following transplantation. Pred- 
nisone doses were similar in the first two groups. The 
third group of patients also received the triple regimen, 
but with a lower dose of prednisone than the first and 
second groups during the first 3 months following trans- 
plantation. Prednisone dose was reduced to 0.5 mg/kg 
per day as early as 1 week after transplant in the third 
group of patients. At 4 months after transplant, all patients 
were converted to AZA/Pred immunosuppression except 
for some who could afford to continue on CYA or could 
not tolerate AZA. In general, acute rejections were treated 
with pulse steroid therapy OKT3 was used in only five 
patients who could afford it. 
Diagnosis of Infection 
Infection after transplant was diagnosed when two or 
more of the following conditions were met: (1) positive 
culture of a pathogen from urine (>lOO,OOO colonies/ml); 
(2) x-ray and physical fmdings indicative of infection; (3) 
fever over 38°C; (4) antibiotic treatment for confirmed 
infection as judged by the authors (attending physicians); 
and (5) post-mortem or surgical biopsy specimens posi- 
tive for infection. 
Routine microbiologic work-up included fnngal cul- 
ture and serology; special stains (e.g., for Pneumocystis) 
were done as indicated in the protocols. Cytomegalovirus 
was diagnosed by serology or early antigen detection in 
blood, tissues, or bronchoalveolar lavage. 
When an infection was identified, further informa- 
tion regarding dose of immunosuppressive regimen, prior 
rejection episodes, and outcome were also noted. Some 
patients had more than one type of infection at a time. 
When different pathogens were found in different sites, 
each was considered as a separate episode of infection. 
RESULTS 
The pretransplant seroprevalence rates in the study pop- 
ulation were as follows: CMV positive, 99%; EBV, 95%; and 
HBV, 52%.The HBsAg carrier rate was 8.3%. 
The occurrence of infection was highest during the 
first 3 months following transplantation; 54% of the 
patients had one or more infections during this interval. 
Subsequently, the infection rate declined to 23% at 4 to 
6 months and 13% at 7 to 9 months after transplantation. 
During the 10 to 12 months following transplant, the 
infection rate was only 10%. 
Pattern of Infection 
The pattern of infections observed is shown in Table 1. 
In the first 3 months following transplantation, bacterial 
infections accounted for 76% of the total infections that 
developed.This was followed by viral and parasitic infec- 
tions at 10% each. Four to six months after transplant, 
fewer bacterial infections (57%) were observed: 14% were 
due to tuberculosis and 8% were due to Nocur&z.Toward 
the ninth month, more viral and fungal infections were 
noted. More cases of nocardiosis (12%) were observed 
toward the end of the first year after transplantation. 
Pneumonia and urinary tract infection (UTI) were 
the most frequent bacterial infections seen. Klebsiella 
pneumoniae was the most common cause of pneumo- 
nia, and Escherichia coli was the most common cause of 
UTI. Salmonella caused 23% of the bacteremias. Other 
bacterial infections observed were skin and soft tissue 
infections and gastroenteritis. 
Definite viral infection episodes were due to CMV 
(17 cases), herpes roster (13 cases), herpes simplex (13 
cases), varicella (10 cases), and hepatitis (10 cases). 
Epstein-Barr virus was seen in only two patients. 
Months after 
Transplantation 
Table 1. Patterns of Infections among Renal Transplant Recipients 
Percentage of Infections 
Number of Bacterial viral Parasitic Fungal TB Nocardia 
Infections 
o-3 177 76 10 10 2 0 2 
4-6 76 57 13 4 4 14 8 
7-9 42 48 31 2 7 5 7 
10-12 33 58 9 6 9 6 12 
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Table 2. Distribution of Types of Infections according to Table 4. Rejection Episodes among Patients with Double and 
Immunosuppressive Therapy Triple Immunosuppressive Therapy 
AZ4 + Pred CYA + AZA + Pred CYA + Pred 
n = 210 (%j n = 236 (%j n= 130(%) 
Systemic 
fungal 3 (2) 5 (2) 6 (5) 
Viral 35 (17) 17 (7) 13 (10) 
Tuberculosis 7 (3) 7 (3) 10 (8) 
Nocardiosis 13 (6) 3 (1) 1 (0.8) 
Parasitic 4 (2) 11 (5) 11 63) 
Bacterial 148 (70) 193 (82) 89 (68) 
AZ.4 = azathioprine; Pred = prednisone; CYA = cyclosporine. 
Immunosuppressive Therapy 
Double Triple Triple LD 
n (%) n (%) Prednisone n (%) 
Number of patients 139 214 160 
Episodes of rejection 
within (mo): 
l-3 17 (12.2) 21 (9.8) 25 (15.6) 
4-6 6 (4.3) 8 (3.7) 9 (5.6) 
7-9 1 (0.7) 7 (3.3) 6 (3.8) 
IO-12 6 (4.3) 9 (4.2) 8 (5.0) 
Total rejections 30 (21.5) 45 (21 .O) 48 (30.0) 
Most of the observed parasitic infections were intesti- 
nal amoebiasis (13 cases) and malaria (9 cases). Pneu- 
mocystis carinii pneumonia (PCP) was seen in only four 
patients, all while on cyclosporine. Five female patients 
had trichomoniasis and one patient had giardiasis. 
Tuberculosis developed in 20 patients and 7 had dis- 
seminated disease. Nocardiosis was seen in 18 patients. 
The deep-seated or systemic fungal infections seen were 
mucormycosis (6) cryptococcosis (4) disseminated can- 
didiasis (3) and aspergillosis (3). 
Relation between Immunosuppressive Therapy and 
Infections 
No clear relation to type of immunosuppressive therapy 
was noted, although bacterial infection seemed to be 
more common in patients receiving both azathioprine 
and cyclosporine. More tuberculosis and more fungal and 
parasitic infections occurred in patients receiving 
cyclosporine (Table 2). Nocardiosis more commonly 
occurred in patients on azathioprine. 
Since pneumonia and UT1 accounted for more than 
60% of the bacterial infections, only these two infections 
were considered in relation to immunosuppressive regi- 
mens (Table 3).The proportion of these infections was 
lower with double than with triple therapy However, sta- 
tistical comparison using chi-square test showed that 
there was no significant difference in pneumonia 
Table 3. Bacterial Infections among Patients on Post-transplant 
Immunosuppressive Regimens 
Percentage with 
Regimen Number of Patients Pneumonia UT/ 
LD = low dose 
episodes between regimensThe proportion of UT1 was 
lowest in patients on triple regimen with lower dose 
prednisone. This was significant at P < O.Ol.To find out 
if the difference was due to rejections or rejection ther- 
apy, rejection episodes were compared (Table 4). Double 
and triple regimens had equal total rejection episodes 
(21%).The rejection rate was 30% in the triple regimen 
with low dose prednisone group. Rejection episodes in 
this third group was also higher even within 3 months 
after transplantation (P < 0.05). But it was in this group 
that UT1 episodes were lowest. No correlation between 
rejection and bacterial infections was observed. 
Mortality 
Thirty-five deaths were directly attributed to infection, 
with an overall mortality of 7%.The proportion of those 
who died among the total patient population was ana- 
lyzed according to the immunosuppressive protocol used 
(Table 5). Mortality was highest (11.7%) among those on 
triple regimen. Fifty-five percent of the mortalities 
occurred within the first 3 months after transplantation, 
and 25 to 33% followed acute rejection therapy with high 
dose steroids.The three major causes of death were sep- 
ticemia (lo), bacterial pneumonia (9) and systemic fun- 
gal infection (5). Three patients with CMV pneumonia 
died with concomitant infection, two with pulmonary 
nocardiosis, and one with salmonellosis. One patient with 
Table 5. Fatal Infections Associated with Rejection Therapy 
Protocol 
Double 
n (%) 
Triple LD 
Triple Prednisone 
n (%) n (%) 
Double 
Triple 
Triple low dose 
prednisone 
UTI = urinary tract infection. 
139 17 29 
214 26 38 
160 18 8 
Number of Patients 139 214 160 
Mortality* 6 (4.3) 25 (11.7) 4 (2.5) 
Mortality with rejection therapy 2 (33.5) 8 (32) 1 (25) 
*55% of deaths occurred within the first 3 months after transplantation. 
LD = low dose. 
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initial PCP died with mucormycosis. Two died of fulmi- mean that the infections in these patients on lower dose 
nant HBV; both were positive for HBsAg pretransplant. prednisone were less severe. 
Owing to financial constraints, the immunosuppres- 
DISCUSSION 
sive regimen used in the patients studied may be short 
of the ideal, but with improvements in the dosing regi- 
The pattern of infections observed among the renal trans- 
men of the triple therapy, especially the prednisone dose, 
plant patients studied was similar to that reported from 
severe and fatal infections have been reduced. 
other transplant centers. 1,2,5 Infections were more fre- 
quent during the period when immunosuppression was 
greatest (i.e., in the first 3 months following transplant 
surgery). Bacterial infections due to common pathogens 
and viral infections predominated in the early post-trans- 
plant period. Fungal and TB infections occurred 6 months 
or later in the first post-transplant year. Such observations 
were also noted in earlier reports that describe the types 
of pneumonia observed in renal transplant patients.*-lo 
The triple combination of AZA, CYA, and Pred seemed to 
favor more bacterial infections. 
In contrast to other reports, there was a higher inci- 
dence of tropical diseases, such as amoebiasis, malaria, 
and tuberculosis, which probably reflects the prevalence 
of these diseases in the country.These were more com- 
monly seen in patients receiving cyclosporine. 
Except for HCV the seroprevalence to CM\! EBV, and 
HBV before transplantation reflects the seroprevalence in 
the general Filipino population. Cytomegalovirus reacti- 
vation was seen as co-infection in the infections observed. 
The three patients who died with CMV pneumonia did 
not receive ganciclovir, because the drug was not yet 
available. 
Another type of infection that was observed to be 
common among the patients on azathioprine was nocar- 
diosis.Although the majority of cases presented as pul- 
monary infection, other manifestations also were 
seen.4,“~12 Nocardiosis presenting as subcutaneous 
abscesses, brain abscess, and bacteremia were reported 
in 47 cases.13 
The association of graft rejection and its therapy to 
infection have long been described. Bacterial infections 
follow high dose steroid pulse therapy, whereas viral 
infections, such as CMV and hepatitis are seen after OKT3 
and antithymocyte globulin (ATG) therapy5z14z15 Although 
no direct relation to rejection was observed, an associa- 
tion with antirejection therapy was noted in 25 to 33% 
of the fatal infections in this study. Mortality due to infec- 
tion was lowest in the group of patients who received the 
triple regimen with lower dose prednisone. This may 
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